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Abstract 
Purpose: To assess modifiable clusters of cardiovascular risk factors and patterns of antihypertensive 
drugs use as well as identify clinical characteristics associated with blood pressure control in 
Jordanians.  
Methods: A cross-sectional observational study was conducted in cardiology outpatient clinics at two 
hospitals in Amman, Jordan. Outcomes studied were prevalence of cardiovascular risk factors, patterns 
of antihypertensive medication use, rate of blood pressure control and factors associated with such 
control.  
Results: The number of concomitant medical conditions was high: diabetes mellitus (51 %), 
dyslipidemia (82 %), coronary artery disease (71 %), history of acute coronary syndrome (37 %) or 
coronary revascularization (64 %). Hypertension was controlled in 44 % of patients. Average number of 
antihypertensive medications was 2.38 ± 1.21. The most commonly prescribed monotherapy 
medications were beta-blockers (48 %), followed by angiotensin-converting enzyme inhibitors (ACEIs) 
with 28 % and angiotensin II receptor blockers (ARBs) with 23 %. Among all patients, beta-blockers (67 
%) were also the  most prescribed, followed by ACEIs (47 %) and ARBs (41%). Multivariate logistic 
regression analysis revealed inverse association between BP control and the presence of diabetes 
mellitus. 
Conclusion: There is inadequate cardiovascular risk assessment and control of blood pressure in 
hypertensive patients in Jordan. Several practical measures need to be taken urgently to mitigate these 
deficiencies. 
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Hypertension is a major factor contributing to the 
global disease burden [1,2]. The worldwide 
prevalence of HTN in 2000 was ~26%, affecting 
around 1 billion people. There is considerable 
variation among countries with regard to the 
prevalence (~5  to 70 %) and control rates (~5 to 
58 %) for hypertension [3]. Poor control of 
hypertension can result in ischemic heart 
disease, heart failure, stroke and chronic renal 
insufficiency [2].  
 
Major guidelines for hypertension were published 
in 2003 by World Health Organization 
/International Society of Hypertension [4], JNC-7 
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[5] and European Society of Hypertension–
European Society of Cardiology [6]. 
 
Several studies have found that only 60 % of 
patients with known hypertension receive 
treatment, and in fewer than 50 % of treated 
patients blood pressure was controlled [7]. In the 
USA, only one third of patients with hypertension 
undergoing treatment had their blood pressure 
controlled [5,8]. In Jordan during 2004, about 
400,000 (15 %) adults reported hypertension [9]. 
Very few studies have addressed the 
management of hypertension in this country. A 
study of prevalence, awareness and 
management of hypertension in eastern Jordan 
revealed that 68.5 % of people who were aware 
of their diagnosis did not achieve control of their 
blood pressure [10], and among Bedouins in 
Northern Jordan, 57.1 % of those aware of their 
diagnosis did not achieve control [11]. 
 
The objectives of this study include assessment 
of cardiovascular risk factors prevalence, pattern 
of antihypertensive drugs use, as well as rate of 
blood pressure control and factors associated 







The cross-sectional observational study was 
conducted by specially trained field workers in 
outpatient cardiology clinics in Jordan University 
Hospital and Al-Basheer Hospital in Amman 
between January 1 2007 and April 1 2007. 
Physicians who agreed to participate in the study 
were asked to enroll adult (18 years and above) 
hypertensive patients of both genders. 
Information was collected from medical files and 
during patient interview. Informed consent was 
obtained from every patient, and the study was 
approved by the Research Ethical Committees of 
the Jordan University Hospital and the Jordanian 
Ministry of Health. 
 
Hypertension was defined as prior diagnosis by a 
physician, or known blood pressure values 
>140/90 mm on two or more occasions. 
Modifiable cardiovascular risk factors studied 
were obesity, diabetes mellitus, smoking, 
dyslipidemia and chronic kidney disease. 
Obesity was defined as body mass index (BMI) ≥ 
30 kg/m2, and overweight as BMI ≥ 25 kg/m2, but 
< 30 kg/m2. Current smoking was defined as 
smoking at least one cigarette or  waterpipe (also 
known as a narghile, arghila, hookah , or qalyān) 
per day up to one month before enrollment. 
Diabetes mellitus was defined as prior diagnosis 
by a physician, known fasting plasma glucose 
values ≥ 126 mg/dL, plasma glucose ≥ 200 
mg/dL at any time or current use of hypoglycemic 
medication. Dyslipidemia was defined as prior 
diagnosis by a physician or the presence of one 
or more of the following: low density lipoprotein 
cholesterol  ≥ 140 mg/dL, high density lipoprotein 
cholesterol < 40 mg/dL, or triglycerides > 150 
mg/dL measured after 8 h (or longer) fasting. 
 
Chronic kidney disease was considered to be 
present if the patient had either a decreased 
estimated glomerular filtration rate (GFR) (<60 
ml/min) or persistent albuminurea > 300 mg/dL. 
Estimated GFR was calculated using the 
Modification of Diet in Renal Disease (MDRD) 
formula (for men, 186 x serum creatinine levels -
1.154 x age-0.203; for women, 186 x serum 
creatinine levels-1.154 x age-0.203 x 0.742). 
 
Blood pressure measurement and targets 
 
Blood pressure was measured two times on the 
right arm supported at heart level with a 
conventional (mercury) sphygmomanometer and 
correctly-sized cuff with the participant seated 
after at least 5-min rest, and with 2 min rest 
between each measurement. Systolic blood 
pressure was based on the first Korotkoff phase 
and diastolic blood pressure on the fifth Korotkoff 
phase. The average of the two readings was 
used for analysis.  
 
Hypertension was considered to be controlled if 
systolic blood pressure was < 140 mm Hg and 
diastolic blood pressure < 90 mm Hg for general 
hypertensive population, or systolic blood 
pressure < 130 mm Hg and diastolic blood 
pressure < 80 mm Hg in patients with 
established cardiovascular disease, diabetes 




All data were entered and analyzed using the 
SPSS software (version 16.0; SPSS, Inc, 
Chicago, IL). Chi square (χ2) was used to test 
any significance between categorical variables, 
whereas independent t-test was utilized with non-
categorical variables. All p-values were two-sided 
and p < 0.05 was considered statistically 
significant. Univariate analysis was used to 
determine any association of blood pressure 
control with the categories of patients’ factors 
that were potentially important based on previous 
research and clinical judgment (patient’s gender, 
age, body mass index, duration of hypertension, 
smoking status, number of cardiovascular risk 
factors, presence of cardiovascular disease, 
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diabetes or renal disease, the number and class 
of antihypertensive medications). 
 
To assess the independent contribution of patient 
characteristics to the blood pressure control, we 
conducted multivariate logistic regression 
analysis for variables which demonstrated 
significance (p < 0.05) in univariate analysis. 
Adjusted odds ratio and 95 % confidence 
intervals for the probability of blood pressure 
control were calculated for each predictor to 




Patients' demographic and medical data 
 
The number of patients enrolled was 408. Their 
general and clinical characteristics are presented 
in Table 1. Hypertension was controlled only in 
44 % of patients.  
 
Prevalence of modifiable cardiovascular risk 
factors 
 
Hypertensive patients were checked for 
modifiable cardiovascular risk factors (smoking, 
obesity, diabetes mellitus, dyslipidemia and 
chronic kidney disease). Only 22 patients (5.4 %) 
had no modifiable risk factors, 107 (26.2 %) had 
one, 167 (40.9 %) had two, 92 (22.5 %) had 
three, 20 (4.9 %) had four, and none of the 
patients had five risk factors. 
 
Assessment and management of 
cardiovascular risk factors 
 
Table 2 shows proportion of patients who were 
screened by laboratory or other diagnostic tests 
for presence of cardiovascular risk factors or 
hypertension complications. Unfortunately, data 
on electrocardiogram, abdominal ultrasound, 
echocardiography and fundoscopic examination 
were not available in medical files. 
 
Treatment of hypertension 
 
Table 3 shows the proportion of patients 
receiving different numbers of antihypertensive 
medications. The mean number of 
antihypertensive medications was 2.38±1.21 per 
patient.  
 
Pattern of antihypertensive medications is shown 
in Table 4. The most commonly prescribed class 
as monotherapy was beta-blockers, followed by 
angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, and calcium 
channel blockers. Thiazides accounted to a very 
small number of cases. Similar pattern was 
observed in the complete sample of patients 
receiving antihypertensives.  
 
Table 1: Patients' demographic and medical data (N = 
408)  
 







Age, yrs, mean ± SD (range) 58.60±10.85 
(20-89) 
Smokers 62 (15.2) 
BMI, mean ± SD 31.02±5.30 
BMI categories 
Normal 








Coronary artery disease 
History of ACS 
History of CR  













HTN duration, yrs, mean ± SD 8.00±6.96 
SBP, mm Hg, mean ± SD 138.52±19.16 
DBP, mm Hg, mean ± SD 83.09±10.90 
BP controlled 177 (43.6) 
Total cholesterol, mg/dL, mean ± SD 192.01±64.15 
LDL cholesterol, mg/dL, mean ± SD 118.32±49.30 
HDL cholesterol, mg/dL, mean ± SD 44.36±23.73 
Triglycerides, mg/dL, mean ± SD 201.30±118.27 
FPG, mg/dL, mean ± SD  138.33±62.13 
ACS-acute coronary syndrome (myocardial infarction or 
unstable angina), BMI – body mass index, BP – blood 
pressure, COPD – chronic obstructive pulmonary disease, 
CKD – chronic kidney disease, CR – coronary 
revascularization, CV – cardiovascular, DM – diabetes 
mellitus, DBP – diastolic blood pressure, FPG – fasting 
plasma glucose, HbA1C –  glycosylated hemoglobin, HDL – 
high density lipoprotein, IDDM – insulin-dependent diabetes 
mellitus, LDL – low density lipoprotein, NIDDM – non insulin-
dependent diabetes mellitus, SBP – systolic blood pressure  
 
Table 2: Investigations done for the assessment and 
management of cardiovascular risk in hypertension 
patients (N = 408)  
 
Investigation N (%) 
Urine for albumin 87 (21.3) 
Serum creatinine or BUN 303 (74.3) 
Plasma glucose or HbA1c 295 (72.3) 
Total cholesterol 285 (69.9) 
Lipid fractions 255 (62.5) 
ECG NA 
Abdominal US NA 
Echocardiography NA 
Fundoscopic examination NA 
 
BUN – blood urea nitrogen, HbA1c – glycated hemoglobin, 
ECG – electrocardiogram, 
US - ultrasound 
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Table 3: Number of antihypertensive drugs used (N = 
408)* 
 
Drug N (%) or 
mean±SD 
No drug 17 (4.2) 
One drug 91 (22.3) 
Two drug combination 111 (27.2) 
Three drug combination 114 (27.9) 
More than 3 drug combinations 75 (18.4) 
Number of antiHTN medications 
used, mean (±SD) (range) 
2.38±1.21 (0-6) 
 
Among patient characteristics studied by 
univariate logistic regression analysis, duration of 
hypertension, presence of diabetes mellitus, 
peripheral arterial disease, heart failure and 
history of acute coronary syndrome were 
inversely associated, while angiotensin receptor 
blockers were positively associated with 
achievement of BP control (Table 5).  
 
Table 4: Distribution of antihypertensive prescriptions 
according to medications class for patients receiving 
monotherapy and for the complete sample of patients 
receiving pharmacotherapy  
 







ACEIs 25 (27.5) 193 (47.3) 
ARBs 21 (23.1) 168 (41.2) 
BRBs 44 (48.4) 272 (66.7) 
CCBs 13 (14.3) 125 (30.6) 
Thiazides 5 (5.5) 124 (30.4) 
Loop diuretics 0 (0) 89 (21.8) 
Potassium-sparing agents 0 (0) 55 (13.5) 
Other antihypertensives 1 (1.1) 16 (3.9) 
ACEIs – angiotensin converting enzyme inhibitors, ARBs – 
angiotensin receptor blockers, BRBs – beta blockers, CCBs – 
calcium channel blockers 
 
In the final multivariate logistic regression model, 
only the presence of diabetes mellitus was 
inversely associated with hypertension control 
(Odds Ratio 0.50; 95% Confidence Interval 0.32-




The benefit of blood pressure reduction with 
antihypertensive drug treatment has become 
increasingly evident, with decreases in both all-
cause mortality and coronary artery disease as 
shown by multiple clinical trials and 
epidemiological studies [12]. In 2004 in the US, 
blood pressure control rates were 61.4 % in men 
and 35.1 % in women [13]. In our study, despite 
the average number of antihypertensive 
medications being 2.38, the blood pressure 
control rate was only about 44 %, suggesting that 
hypertensive patients are not treated 
aggressively enough. 
 
Comparing our results to other studies conducted 
in Jordan, blood pressure control rate among 
hypertensive patients who attend cardiology 
clinics in Amman, the capital of Jordan (44%), is 
higher than in eastern Jordan (31 %) [10], and 
close to Bedouins in Northern Jordan (43 %) 
[11].  
 
Clustering of three or more metabolic syndrome 
components increases the incidence of 
cardiovascular disease, and the identification and 
management of additional risk factors should be 
encouraged to prevent cardiovascular events in 
hypertensive patients [14]. Among hypertensive 
patients in our study, 96.6 % had one or more 
and 27.4 % had three or more additional risk 
factors. Our data are in agreement with the 
finding from the Framingham Heart Study that 
almost 80 % of patients with hypertension had at 
least one additional cardiovascular risk factor, 
while 30 % of men and 32 % of women with 
hypertension had three or more additional risk 
factors [15]. Our data also support results from 
other studies that more than 50 % of 
hypertensive patients had diabetes, dyslipidemia, 
or obesity [14,16]. 
 
Past studies emphasized that assessment of 
global cardiovascular risk and titration of multiple 
antihypertensive drugs are considered to be 
important for achievement of blood pressure 
goals in the majority of patients [1]. In our study, 
investigations for assessment and management 
of cardiovascular risk factors/diseases were not 
always available – despite high prevalence of 
cardiovascular and associated diseases such as 
diabetes mellitus, dyslipidemia, coronary artery 
disease, heart failure and chronic renal disease. 
 
The prescription patterns of antihypertensives 
vary from one country to another [17]. In a study 
conducted in USA in 2004, diuretics were 
prescribed at a rate of 33%, calcium channel 
blockers 26%, angiotensin-converting enzyme 
inhibitors 34%, angiotensin receptor blockers 
25%, and beta-blockers 19 % of hypertension 
visits [18]. In a cross-sectional, population-based 
survey in Ontario, Canada, of all hypertensives, 
51 and 49 % were on monotherapy compared to 
2+ drug therapy with similar control rates (86 % 
vs. 80 % respectively). In those on monotherapy, 
a renin-angiotensin system blocker was the most 
commonly used drug class (62 %), and use of 
other drug classes was only approximately 10 %. 
In those on 2+ drug therapy, a renin-angiotensin 
system blocker was also the most common class 
(80 %), followed by a diuretic (67 %) [19]. In this  
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Table 5: Factors associated with BP control in univariate logistic regression analysis: demographic factors and 
factors related to hypertension 
   
Characteristic, number (%) or 
mean±SD 
%BP controlled %BP not 
controlled 
Odds Ratio [95% 
CI] 
p-value 
Age  58.1±11.0 59.0±10.8 -3.07 - 1.25 >0.05 
Gender 
   Female 













BMI 30.6±5.2 31.3±5.3 -1.79 – 0.34 >0.05 
HTN duration 7.1±5.8 8.7±7.7 -3.02 - -0.52 0.04 

































































































   Yes 














   Yes 













   Yes 













Peripheral vascular disease 
   Yes 














   Yes 














   Yes 













History of ACS 
   Yes 













History of CR 
   Yes 














   Yes 














   Yes 













# CV risk factors 1.85±0.98 2.03±0.92 -0.36 – 0.01 >0.05 
ACEI –angiotensin-converting enzyme inhibitors, ARB –angiotensin receptor blocker, BMI –body mass index, BRB – beta-
receptor blocker, ACS – acute coronary syndrome, CAD – coronary artery disease, CKD –chronic kidney disease, CR –
coronary revascularization, CV -cardiovascular, DM – diabetes mellitus, HF – heart failure, HTN –hypertension and CI – 
confidence interval 
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study, only 22% received monotherapy, while 
about 73 % were on two ore more 
antihypertensive drugs. The most commonly 
prescribed class of antihypertensives in our study 
was beta-blockers, both as monotherapy (48 %) 
and in compete sample of patients who receive 
antihypertensive drugs (67 %). The second most 
commonly prescribed class of agents in the 
complete sample was angiotensin-converting 
enzyme inhibitors (47 %), followed by 
angiotensin receptor blockers (41 %), calcium 
channel blockers (31 %), thiazides (30 %), loop 
agents (22 %) and potassium-sparing diuretics 
(14 %).  
 
Our results are consistent with other studies 
where, despite increased awareness and 
treatment of hypertension, individuals with a 
higher risk of coronary artery disease had higher 
rates of uncontrolled blood pressure compared 
with the average-risk population [20]. Many other 
factors are likely to contribute to suboptimal rates 
of hypertension control: insufficient or 
inappropriate treatment, lack or unaffordability of 
drugs, insufficient patient knowledge about 
disease and/or medications, barriers to 
implement healthy life style, insufficient follow-up, 
and poor adherence. Among clinical and 
medication characteristics studied in multivariate 
logistic regression analysis, only presence of 
diabetes mellitus was inversely associated with 
BP control. In contrast to our results, control 
rates in Canadian study did not differ in the 
overall hypertensive population and those with 
comorbidity [19].  
 
Limitations of the study 
 
The patient sample, while representative of the 
population receiving primary care mainly in urban 
clinic may not be representative of all adults with 
hypertension in Jordan; consequently, the 
hypertension control rates and patterns of 
medication use may be overestimated. 
Hypertension could be recognized and treated by 
other specialists, but our data focused on 
cardiologists. We did not study the effects of 
patient education level, lifestyle and medication 
adherence, income and insurance status on the 
blood pressure control.  Physician’s charac-
teristics that may also impact hypertension 
control were not investigated. In addition, 
because of the cross-sectional design, there was 
no assessment whether the present therapy was 
the initial one or whether it replaced or amended 
the original one. Another limitation of this study 
was the possible selection of the individuals at 
higher cardiovascular risk among people coming 
to their cardiologists for the treatment of their 
high blood pressure compared to the general 
hypertensive population. Still, this group of 
patients would receive immediate benefit if a 
more “aggressive” treatment approach was used. 
Further large interventional studies are needed in 
hypertensive population in Jordan, addressing all 




The prevalence of cardiovascular risk factors, 
such as smoking, obesity, diabetes, dyslipidemia, 
CKD was high in hypertensive patients.  
Alarmingly, there is inadequate cardiovascular 
risk assessment and control of blood pressure in 
hypertensive patients in Jordan. Several practical 
measures need to be taken urgently: developing 
national strategic plan to improve hypertension 
and cardiovascular risk factors control, 
encouraging patients to maintain healthy lifestyle, 
pharmacy-directed interventions (e.g., availability 
and prescription of generic drugs) and initiatives 
directed toward physicians (e.g., clinical 
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